Furthermore, addition of the CB1R antagonist Rimonabant [100 nM] to ART27.13 treated myotubes in the cancer cachexia model had no impact on the protective affect against myotube degeneration provided by ART27.13 [100 nM], in either the SW480 or H1299 cancer cachexia cell model (Figure 6c and 6d, respectively). Here, CNR1 is linked to cancer.